Apellis Pharmaceuticals Inc (FRA:1JK)
€ 36.59 -0.37 (-1%) Market Cap: 4.53 Bil Enterprise Value: 4.33 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 49/100

Apellis Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 09, 2022 / 05:50PM GMT
Release Date Price: €40 (+6.95%)
Phil Nadeau
Cowen and Company, LLC - Analyst

Good afternoon and welcome to Cowen and Company's 42nd Annual Health Care Conference, hopefully its last virtual edition. I'm Phil Nadeau, one of the biotech analysts here at Cowen. It's my pleasure to moderate a fireside chat with Apellis Pharmaceuticals today. We have Tim Sullivan and Cedric Francois sharing a screen. We're really happy to have you guys with us today. And Adam Townsend, Chief Commercial Officer, is also here, apparently in a different room.

Thanks so much for joining us, guys. Really appreciate it. We know these are exciting times for Apellis with one launch going in now and an FDA filing coming up shortly.

Questions & Answers

Phil Nadeau;Cedric Francois
Cowen and Company, LLC - Analyst;Apellis Pharmaceuticals, Inc. - Co-Founder, CEO &

So, Cedric, maybe I'll hand it to you. Can you give us a brief state of the company overview, biggest strengths, biggest challenges, what needs to happen to drive outperformance over the next year or two?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot